Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– ...

Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & ...

Kiniksa is on track to initiate a Phase 2/3 clinical trial designed to evaluate the efficacy and safety of KPL-387 administered subcutaneously (SC) in patients with recurrent pericarditis. The trial ...

Via Luigi Cibrario 72, 10141 Torino, Italy, massimo_imazio{at}yahoo.it, massimo.imazio{at}unito.it Objective Data on the incidence of new onset atrial fibrillation and flutter (AF/f) in patients with ...

The country singer is dealing with a frustrating vocal issue while also managing pericarditis, a heart condition she’s had ...

Furthermore, it was found that myocardial insufficiency and hypervolemia were not only important causative agents in the circulatory dysfunction but were in some measure reversible, thus permitting ...

A document circulated to members of Congress misinterprets studies and cites debunked research, scientists say. It could ...

Autoinflammatory diseases predominantly affect young patients, many of whom may go on to become pregnant. For many ...

Both vaccines previously carried warnings about how the risk of the heart side effects — which doctors call myocarditis (an inflammation of the heart muscle) and pericarditis (inflammation of ...